Supraglottal injection of botulinum toxin type a in adductor type spasmodic dysphonia with both intrinsic and extrinsic hyperfunction

Laryngoscope

Volumn 108, Issue 1, 1998, Pages 55-63

  Schönweiler, Rainer ^a   Wohlfarth, Kai ^b   Dengler, Reinhard ^a   Ptok, Martin ^b  

^a Center of Otolaryngology Head and Neck Surgery and Ophthalmology   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DYSPHONIA; FEMALE; GLOTTIS; HUMAN; HYPERACTIVITY; INJECTION; MALE; MUSCLE CELL; MUSCLE SPASM; PHONATION; PRIORITY JOURNAL; VOCAL CORD; VOICE;

ACOUSTICS; ADULT; AGED; BOTULINUM TOXIN TYPE A; FEMALE; HUMANS; INJECTIONS; LARYNGOSCOPY; MALE; MIDDLE AGED; NEUROMUSCULAR AGENTS; VIDEO RECORDING; VOICE DISORDERS;

EID: 0345698826     PISSN: 0023852X     EISSN: 15314995     Source Type: Journal    
DOI: 10.1097/00005537-199801000-00011     Document Type: Article

References (32)

1. U.S. National Institutes of Health. Botulinum toxin: National Institutes of Health Consensus Development Panel on clinical use of botulinum toxin. J Voice 1992;6:394-400.
2. Woo P, Colton R, Casper J, et al. Analysis of spasmodic dysphonia by aerodynamic and laryngostroboscopic measurements. J Voice 1992;6:344-51.
3. Zwirner P, Murry T, Swenson M, et al. Effects of botulinum toxin therapy in patients with adductor spasmodic dysphonia: acoustic, aerodynamic, and videoendoscopic findings. Laryngoscope 1992;102:400-6.
4. Zwirner P, Murry T, Woodson GE. A comparison of bilateral and unilateral botulinum toxin treatments for spasmodic dysphonia. Eur Arch Otorhinolaryngol 1993;250:271-6.
5. Blasi J, Chapman ER, Link E, et al. Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25. Nature 1993;365:160-3.
6. Cichon JV Jr, McCaffrey TV, Litchy WJ, et al. The effect of botulinum toxin type A injection an compound muscle action potential in an in vivo rat model. Laryngoscope 1995;105:144-8.
7. Ludlow CL, Naunton RF, Sedory SE, et al. Effects of botulinum toxin injections on speech in adductor spasmodic dysphonia. Neurology 1988;38:1220-5.
8. Blitzer A, Brin MF. Laryngeal dystonia: a series with botulinum toxin therapy. Ann Otol Rhinol Laryngol 1991;100:85-9.
9. Ford CN, Bless DM, Patel NY. Botulinum toxin treatment of spasmodic dysphonia: techniques, indications, efficacy. J Voice 1992;6:370-6.
10. Woodson GE, Zwirner P, Murry T, et al. Use of flexible fiberoptic laryngoscopy to assess patients with spasmodic dysphonia. J Voice 1991;5:85-91.
11. Kruse E. The mechanism of the ventricular fold voice: a critical alternative response to the concepts of Rethi. Folia Phoniatr(Basel) 1981;33:294-313
12. Sinelnikov RD. Atlas of Human Anatomy. Moscow: Mir; 1989.
13. Kotby MN, Kirchner JA, Kahane JC, et al. Histo-anatomical structure of the human laryngeal ventricle. Acta Otolaryngol(Stockh) 1991;111:396-402.
14. Von-Doersten PG, Izdebski K, Ross JC, et al. Ventricular dysphonia: a profile of 40 cases. Laryngoscope 1992;102:1296-301.
15. Ludlow CL, Bagley J, Yin SG, et al. A comparison of injection techniques using botulinum toxin injection for treatment of the spasmodic dysphonias. J Voice 1992;6:380-6.
16. Holzer SE, Ludlow CL. The swallowing side effects of botulinum toxin type A injection in spasmodic dysphonia. Laryngoscope 1996;106:86-92.
17. Zwirner P, Murry T, Woodson GE. Perceptual-acoustic relationships in spasmodic dysphonia. J Voice 1993;7:165-71.
18. Kosokovic F, Vecerina S, Cepelja I, et al. Contribution to therapy of dysphonia plica ventricularis. Laryngoscope 1977;87:408-14.
19. Arnold G, Pinto S. Ventricular dysphonia: new interpretation of an old observation. Laryngoscope 1960;70:1608-27.
20. George EF, Zimbler M, Wu BL, et al. Quantitative mapping of the effect of botulinum toxin injections in the thyroarytenoid muscle. Ann Otol Rhinol Laryngol 1992;101:888-92.
21. Castellanos PF, Gates GA, Esselman G, et al. Anatomic considerations in botulinum toxin type A therapy for spasmodic dysphonia. Laryngoscope 1994;104:656-62.
22. Adams SG, Hunt EJ, Charles DA, et al. Unilateral versus bilateral botulinum toxin injections in spasmodic dysphonia: acoustic and perceptual results. J Otolaryngol 1993;22:171-5.
23. Maloney AP, Morrison MD. A comparison of the efficacy of unilateral versus bilateral botulinum toxin injections in the treatment of adductor spasmodic dysphonia. J Otolaryngol 1994;23:160-4.
24. Quinn N, Hallett M. Dose standardization of botulinum toxin. Lancet 1989;664.
25. Goodnough MC, Johnson EA. Stabilization of botulinum toxin type A during lyophilization. Appl Environ Microbiol 1992;58:3426-8.
26. Hambleton P, Pickett AM. Potency equivalence of botulinum toxin preparations. J R Soc Med 1994;87:719.
27. Durif F. Clinical bioequivalence of the current commercial preparations of botulinum toxin. Eur Neurol 1995;2:17-8.
28. Aronson AE, McCaffrey TV, Litchy WJ, et al. Botulinum toxin injection for adductor spastic dysphonia: patient self-ratings of voice and phonatory effort after three successive injections. Laryngoscope 1993;103:683-92.
29. Murry T, Cannito MP, Woodson GE. Spasmodic dysphonia. Emotional status and botulinum toxin treatment. Arch Otolaryngol Head Neck Surg 1994;120:310-6.
30. Davidson BJ, Ludlow CL. Long-term effects of botulinum toxin injections in spasmodic dysphonia. Ann Otol Rhinol Laryngol 1996;105:33-42.
31. Deliyski D, Orlikoff R. Computer system for multi-dimensional analysis of voice and electroglottographic signals. Thesis presented at the Annual Convention of the American Speech-Language-Hearing Association, Atlanta, GA, November 1991.
32. Izdebski K. Symptomatology of adductor spasmodic dysphonia: a physiologic model. J Voice 1992;6:306-19.